For example, SureSeqTM panels were designed for analysis of AML and MPN cases, but it lacked essential genes for the study of MDS, such as genes involved in splicing (SF3B1, SRSF2, ZRSR2), epigenetic regulation (EZH2), transcriptional regulation (GATA2) or signal transduction (CBL) [22][23][24][25]. This evidence concerns the gene GATA2 and myeloproliferative neoplasm.